Treatment of Cryptococcal Meningitis
The recommended treatment for cryptococcal meningitis is induction therapy with amphotericin B deoxycholate (0.7-1.0 mg/kg/day) plus flucytosine (100 mg/kg/day) for 2 weeks, followed by fluconazole (400 mg/day) for 8 weeks as consolidation therapy, and then fluconazole (200 mg/day) for maintenance. 1, 2
Treatment Approach Based on Patient Population
HIV-Infected Patients
Induction Phase (First 2 weeks):
- First-line: Amphotericin B deoxycholate (0.7-1.0 mg/kg/day IV) plus flucytosine (100 mg/kg/day orally in 4 divided doses) for 2 weeks 1, 2
- For renal concerns: Liposomal amphotericin B (3-4 mg/kg/day) or ABLC (5 mg/kg/day) plus flucytosine 1
- For flucytosine-intolerant patients: Amphotericin B alone for 4-6 weeks 1
Consolidation Phase (Next 8 weeks):
Maintenance Phase:
Antiretroviral Therapy:
Non-HIV, Non-Transplant Patients
Induction Phase:
Consolidation Phase:
- Fluconazole 400 mg daily for 8-10 weeks 1
Maintenance Phase:
- Optional: Fluconazole 200 mg daily for 6-12 months 1
Transplant Recipients
Induction Phase:
Consolidation and Maintenance:
Management of Complications
Increased Intracranial Pressure
- Measure opening pressure during initial lumbar puncture 1
- For pressure >200 mm H₂O, perform daily lumbar punctures to reduce pressure 1, 2
- Consider CSF shunting for patients who don't tolerate or respond to repeated lumbar punctures 1
Monitoring Treatment Response
- Perform follow-up lumbar puncture after 2 weeks of treatment to document CSF sterilization 1
- Patients with positive cultures at 2 weeks may require longer induction therapy 1
- Monitor renal function, electrolytes, and complete blood counts regularly during amphotericin B therapy 2, 4
Alternative Regimens
- When amphotericin B cannot be used: Fluconazole (1200 mg daily) plus flucytosine (100 mg/kg/day) 2, 5
- When flucytosine is unavailable: Amphotericin B plus fluconazole (400-800 mg daily) 2
- Recent evidence suggests single high-dose liposomal amphotericin B (10 mg/kg) plus 14 days of flucytosine and fluconazole may be non-inferior to standard therapy with fewer adverse events 6
Common Pitfalls and Caveats
- Failure to test for HIV in patients with cryptococcal meningitis 1, 2
- Inadequate management of increased intracranial pressure, which is associated with high mortality 1, 2
- Premature initiation of antiretroviral therapy in HIV patients (should wait 2-10 weeks) 1, 2
- Failure to monitor for drug toxicities, especially with amphotericin B (renal toxicity) and flucytosine (bone marrow suppression) 2, 4
- Relying solely on cryptococcal antigen titers to guide treatment decisions 2, 4
- Difficulty distinguishing between treatment failure and immune reconstitution inflammatory syndrome (IRIS) if symptoms worsen during or after treatment 1, 2
Dosage Adjustments
- For flucytosine, monitor serum levels (target: 30-80 μg/mL) and adjust dose based on renal function 1
- For fluconazole in renal impairment: If creatinine clearance ≤50 mL/min, reduce dose by 50%; for hemodialysis patients, give 100% of dose after each dialysis 3
- For pediatric patients: Fluconazole 12 mg/kg on first day, then 6 mg/kg daily for cryptococcal meningitis 3